Table 1.

Immunophenotypic characterisation of untreated hMSCs

CD markers Previous reports Present report
CD10  *  −  
CD31  *,†  −  
CD34  *,†,‡  −  
CD38  */low§  −  
CD44   low*/+†,‡  +  
CD45  *,†,‡  −  
CD73 (SH3)   +  +  
CD90   low*/+†,‡  +  
CD105 (SH2)   +  +  
CD117  *,§  −  
CD147   +§  +  
αSMA   +¶,**  +  
Calponin   +**  +  
Caldesmon I   +**  +  
Myo D    +  
Fibroblast Mab 1 B 10    +  
Fibronectin Mab IST-3   +  +  
Calretinin    −  
Parvalbumin    +  
Nestin  /+  +/−  
NeuN    −  
Neurofilaments    −  
NSE   low  −  
Peripherin    −  
Synaptophysin    −  
Tau    −  
β-III-TUB   +†,‡  +  
GFAP  /low  −  
S100  ‡‡  +  
CNPase    −  
O4    −  
CD markers Previous reports Present report
CD10  *  −  
CD31  *,†  −  
CD34  *,†,‡  −  
CD38  */low§  −  
CD44   low*/+†,‡  +  
CD45  *,†,‡  −  
CD73 (SH3)   +  +  
CD90   low*/+†,‡  +  
CD105 (SH2)   +  +  
CD117  *,§  −  
CD147   +§  +  
αSMA   +¶,**  +  
Calponin   +**  +  
Caldesmon I   +**  +  
Myo D    +  
Fibroblast Mab 1 B 10    +  
Fibronectin Mab IST-3   +  +  
Calretinin    −  
Parvalbumin    +  
Nestin  /+  +/−  
NeuN    −  
Neurofilaments    −  
NSE   low  −  
Peripherin    −  
Synaptophysin    −  
Tau    −  
β-III-TUB   +†,‡  +  
GFAP  /low  −  
S100  ‡‡  +  
CNPase    −  
O4    −  

Constitutive expression of CD and lineage-specific markers by hMSCs cultured in standard growth medium as determined by immunostaining: +, most cells positive; low, few cells positive; −, negative. Our data are compared to those of previous studies: *Reyes et al., 2001; Tondreau et al., 2004; Woodbury et al., 2000; §Colter et al., 2001; Kinner et al., 2002; **Galmiche et al., 1993; ††Lodie et al., 2002; ‡‡Deng et al., 2001.

Close Modal

or Create an Account

Close Modal
Close Modal